Ovarian Clear Cell Carcinoma Clinical Trial
Official title:
Zimberelimab Combined With Metformin in the Treatment of Recurrent Ovarian Clear Cell Carcinoma: A Pilot Study
This study aims to evaluate the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma.
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that PD-1 inhibitors may have clinical benefits for OCCC patients. This single-arm, single-center, pilot study evaluates the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01914510 -
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Recruiting |
NCT03405454 -
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT05600998 -
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
|
N/A | |
| Recruiting |
NCT06065462 -
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05099978 -
Asian Multicenter Prospective Study of ctDNA Sequencing
|
||
| Not yet recruiting |
NCT06279104 -
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
|
||
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05226507 -
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
|
Phase 3 | |
| Recruiting |
NCT04735861 -
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02866370 -
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
|
Phase 2 |